Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized support after first psychosis: a 3-Year test

NCT ID NCT05116514

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether regular, personalized follow-up by a trained case manager can reduce the chance of another psychotic episode over three years in people aged 16 to 30 who have just had their first episode. 256 participants will be randomly assigned to either standard care or case management. The goal is to see if this approach can be rolled out widely to improve recovery and prevent relapse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
case management (regular personalized follow-up by a trained case manager)
What this could lead to
If it works, this could provide a scalable way to improve long-term outcomes for young people after a first psychotic episode, reducing relapse and hospitalizations.
What could go wrong
This is an open-label study, so both patients and staff know who gets the intervention, which can bias results. It is also relatively small (256 people) and focuses on a specific age group, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 256 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient or their close relative must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient is available for a 3-year follow-up. * Patient is managed in a psychiatric service (consultation or hospitalization) for a first episode psychosis defined by: * Presence of positive psychotic symptoms (delusion(s) and/or hallucination(s) and/or conceptual disorganization) evolving for at least one week, either daily or at least 3 times per week for at least one hour per occasion ; * Never having taken a neuroleptic treatment with antipsychotic aim (except for an antipsychotic treatment started for the current episode for example by the general practitioner before being referred to psychiatry); * A disorder meeting the DSM 5 criteria from the following list: delusional disorder, brief psychotic disorder greater than 7 days, schizophreniform disorder, schizophrenia, schizoaffective disorder, substance-induced psychotic disorder greater than 7 days, other specific or nonspecific schizophrenic spectrum disorder or other psychotic disorder, bipolar I or II disorder with congruent and non-mood congruent psychotic features, bipolar disorder with congruent and non-mood congruent psychotic features induced by a substance, major depressive disorder with congruent and non-mood congruent psychotic features. * Inclusion should be within the first 3 months of care for first episode psychosis in the psychiatric service. * At the time of inclusion, the psychotic symptomatology observed during the first episode psychosis may still be present or in remission. Exclusion Criteria: * The subject is participating in another category I interventional study, or is in a period of exclusion determined by a previous study * The subject, or one of the parents for minor patients, refuses to sign the consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * The patients has an IQ less than or equal to 55 * The patient has a first psychotic episode linked to a psychotic problem triggered by a medication of other medical condition * The patient is pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychotic episode are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Saint Marie Clermont-Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • CHU Nice

    NOT_YET_RECRUITING

    Nice, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Nîmes

    RECRUITING

    Nîmes, France

  • CHU de TOULOUSE

    NOT_YET_RECRUITING

    Toulouse, Choisir Une Région, 31, France

  • Centre Hospitalier Léon-Jean Grégory

    RECRUITING

    Thuir, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.